


PHARMACEUTICAL 2023

REVELATION BIOSCIENCES INC. Rank 387 of 446







PHARMACEUTICAL 2023

REVELATION BIOSCIENCES INC. Rank 387 of 446

The relative strengths and weaknesses of REVELATION BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REVELATION BIOSCIENCES INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 13% points. The greatest weakness of REVELATION BIOSCIENCES INC. is the variable Net Income, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -181%, being 224% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,413
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,451
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	35
Other Revenues	0
Property and Equipment	90
Research and Development	5,377
Selling, General and Administrative Expense	5,487

Output Variable	Value in 1000 USD
Assets	5,503
Liabilities	4,451
Expenses	10,865
Revenues	0
Stockholders Equity	1,052
Net Income	-10,830
Comprehensive Net Income	-10,830
Economic Capital Ratio	-181%

